Sarcopenia Musculoskeletal Diseases
Conditions
Interventions
Participants will be randomized according to a computer-generated randomization sequence in a 1:1 ratio to either:
1. The music-based multitask exercise intervention (i.e., Jaques-Dalcroze Eurhythmics
60-min duration).
All subjects are followed-up for 12 months from randomization and asked to attend three clinical visits in addition to the screening visit (i.e., at baseline, 6 months and 12 month
Sponsors
Geneva University Hospitals
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age =65 years (no upper age limit) 2. Short Physical Performance Battery (SPPB) score between 3 and 9, inclusive 3. Presence of low muscle mass according to the Baumgartner definition 4. Able to complete the 400 m walk test within 15 minutes without sitting or the help of another person, or the use of a walker 5. Willingness to give informed consent, to be randomized to one of the two study groups, and comply with all study requirements
Exclusion criteria
Exclusion criteria: People are excluded from participation in the study for any condition likely to affect the safety of the intervention and/or limit lifespan, or factors that may limit adherence to intervention or affect conduct of the trial (e.g., physical limitations should not be clearly attributable to the direct effect of a specific disease). In particular, exclusion criteria applied are: 1. Resides in a nursing home or is hospitalized 2. Diagnosis of dementia or score <21 on the MMSE 3. Serious neurological, neuromuscular or orthopaedic condition (e.g.,Parkinson's disease) 4. Serious cardiovascular or pulmonary condition (including myocardial infarction in previous 6 months) or development of chest pain or severe shortness of breath on the 400 m walk test 5. Participation in a supervised music-based multitask exercise program in the past 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physical performance, measured with the Short Physical Performance Battery (SPPB) score at baseline, 6 and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Skeletal muscle health (including muscle strength and muscle mass, assessed by dynamometry and dual-energy X-ray absorptiometry, respectively) at baseline, 6 and 12 months 2. Sarcopenia status according to cut-off points for sarcopenia at baseline, 6 and 12 months 3. Other physical performances (including gait speed, five times sit-to-stand test time and Timed Up & Go tests) at baseline, 6 and 12 months 4. Balance (including simplified Tinetti test) measured at baseline, 6 and 12 months 5. Cognitive performance, measured with a comprehensive neuropsychological battery assessing different aspects of executive functioning at baseline, 6 and 12 months 6. Incidence of falls and injurious falls, measured with prospective daily recording using calendars at baseline, 6 and 12 months 7. Mobility disability (including 400m walk test) at baseline, 6 and 12 months 8. Quality of life (including SF-36, SarQol) at baseline, 6 and 12 months | — |
Countries
Switzerland
Outcome results
None listed